Relaxation effect of phosphodiesterase-5 inhibitor on the animal bladder and prostatic urethra: In vitro and in vivo study

Urologia Internationalis

Volumn 84, Issue 2, 2010, Pages 231-235

  Lee, Jeong Gu ^a   Moon, Du Geon ^a   Kang, Seok Ho ^a   Cho, Dae Yeon ^a   Park, Hong Seok ^a   Bae, Jae Hyun ^a  

^a Korea University Ansan Hospital   (South Korea)

Author keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; Phosphodiesterase 5 inhibitor; Udenafil

Indexed keywords

ADRENALIN; CARBACHOL; PHENYLEPINEPHRINE; UDENAFIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER; BLADDER PRESSURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FORCE TRANSDUCER; IN VITRO STUDY; IN VIVO STUDY; LOWER URINARY TRACT SYMPTOM; MALE; MUSCLE CONTRACTION; MUSCLE RELAXATION; NONHUMAN; OSCILLATION; PERFUSION PRESSURE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RABBIT; RAT; URETHRA; URETHRA PRESSURE; URODYNAMICS;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MUSCLE, SMOOTH; PHOSPHODIESTERASE INHIBITORS; PROSTATE; PROSTATIC HYPERPLASIA; PYRIMIDINES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; URETHRA; URINARY BLADDER; URINARY TRACT; URODYNAMICS;

EID: 77949420591     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000277604     Document Type: Article

References (25)

1. Hampel C, Gillitzer R, Pahernik S, Hohenfellner M, Thuroff JW: Epidemiology and etiology of overactive bladder. Urologe A 2003;42:776-786.
2. Gacci M, Bartoletti R, Figlioli S, et al: Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. BJU Int 2003;91:196-200.
3. Mulhall JP, Guhring P, Parker M, Hopps C: Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006;3:662-667.
4. Kang KK, Kim JM, Yu JY, Ahn BO, Yoo M, Kim YC: Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia. Int J Urol 2007;14:946-951.
5. Tinel H, Stelte-Ludwig B, Hutter J, Sandner P: Preclinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006;98:1259-1263.
6. Oh TY, Kang KK, Ahn BO, Yoo M, Kim WB: Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res 2000;23:471-476.
7. McMurray G, Casey JH, Naylor AM: Animal models in urological disease and sexual dysfunction. Br J Pharmacol 2006;147(suppl 2):S62-S79.
8. Bae JH, Jung PB, Lee JG: The effects of α-adrenoceptor antagonists on the urethral perfusion pressure of the female rat. BJU Int 2005;96:1131-1135.
9. Jung SY, Fraser MO, Ozawa H, et al: Urethral afferent nerve activity affects the micturition reflex; implication for the relationship between stress incontinence and detrusor instability. J Urol 1999;162:204-212.
10. Bae JH, Moon DG, Lee JG: The effects of a selective noradrenaline reuptake inhibitor on the urethra: an in vitro and in vivo study. BJU Int 2001;88:771-775.
11. Masuda H, Ogawa T, Kihara K, Chancellor MB, de Groat WC, Yoshimura N: Effects of anaesthesia on the nitrergic pathway during the micturition reflex in rats. BJU Int 2007;100:175-180.
12. 1-Adrenergic mechanism in diabetic urethral dysfunction in rats. J Urol 2005;173:1027-1032.
13. McVary KT: Medical therapy for benign prostatic hyperplasia progression. Curr Urol Rep 2002;3:269-275.
14. 1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. J Urol 2006;176:1236-1241.
15. 2-adrenoceptors on bladder activity induced by bladder distension in anaesthetized rat. BJU Int 2000;85:925-931.
16. 2α on contractility and cAMP and cGMP contents in lower urinary tract smooth muscle. Urol Int 1994;52:200-203.
17. Dokita S, Smith SD, Nishimoto T, Wheeler MA, Weiss RM: Involvement of nitric oxide and cyclic GMP in rabbit urethral relaxation. Eur J Pharmacol 1994;266:269-275.
18. G-nitro-L-arginine inhibits non-adrenergic, non-cholinergic relaxation in rabbit urethral smooth muscle. Life Sci 1991;48:2429-2436.
19. Doh H, Shin CY, Son M, et al: Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res 2002;25:873-878.
20. Qiu Y, Kraft P, Craig EC, Liu X, Haynes-Johnson D: Identification and functional study of phosphodiesterases in rat urinary bladder. Urol Res 2001;29:388-392.
21. Drescher P, Eckert RE, Madsen PO: Smooth muscle contractility in prostatic hyperplasia: role of cyclic adenosine monophosphate. Prostate 1994;25:76-80.
22. McVary KT, Roehrborn CG, Kaminetsky JC, et al: Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-1407.
23. McVary KT, Siegel RL, Carlsson M: Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of baseline body mass index or LUTS severity. Urology 2008;72:575-579.
24. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E: A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236-1244.
25. Maggi CA, Giuliani S, Santicioli P, Meli A: Analysis of factors involved in determining urinary bladder voiding cycle in urethane-anesthetized rats. Am J Physiol 1986;251:R250-R257.